0000000000471384

AUTHOR

Rolando Cimaz

showing 47 related works from this author

Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease

2019

Background and Objective: Only a few studies have reported long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD). Herein we report on the effectiveness of anakinra (ANA), expressed in terms of drug retention rate (DRR), and evaluate the predictive factors of drug survival in a cohort of patients with sJIA and AOSD. Patients and Methods: This is a multicenter study reviewing retrospectively the medical records from 61 patients with sJIA and 76 with AOSD, all treated with ANA in 25 Italian tertiary referral centers. Results: The cumulative retention rate of ANA at 12-, 24-, 48-, and 60-month of follow-up was 7…

0301 basic medicineAdult onset Still diseasemedicine.medical_specialtyArthritisStill DiseaseAdult onset Still disease; Anakinra; Drug retention rate; Innovative biotechnologies; Interleukin 1-beta; Personalized medicine; Systemic juvenile idiopathic arthritis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticaanakinra interleukin 1-beta innovative biotechnologies drug retention rate systemic juvenile idiopathic arthritis adult onset Still disease personalized medicineSystemic juvenile idiopathic arthritisInternal medicinemedicinePharmacology (medical)Adverse effectOriginal ResearchPharmacologyAnakinrabusiness.industryHazard ratiolcsh:RM1-950Innovative biotechnologiesmedicine.diseaseDrug retention ratePersonalized medicineConfidence intervalAdult onset Still disease Anakinra Drug retention rate Innovative biotechnologies Interleukin 1-beta Personalized medicine Systemic juvenile idiopathic arthritisDiscontinuation030104 developmental biologylcsh:Therapeutics. PharmacologyAnakinraInnovative biotechnologie030220 oncology & carcinogenesisCohortInterleukin 1-betabusinessmedicine.drug
researchProduct

Proceedings Of The 23Rd Paediatric Rheumatology European Society Congress: Part Two

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

2019

Background: Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile idiopathic arthritis (JIA). However, so far the JADAS has been validated only in children with the non-systemic categories of JIA. Objectives: To develop and validate the systemic JADAS (sJADAS), a new version of the JADAS specific to systemic JIA (sJIA). Methods: The sJADAS is made up by adding a fifth item, named Systemic Manifestation Score (SMS), to the four items included in the original tool (physician global assessment of disease activity, parent/patient global assessment of well-being, active joint count and ery…

Settore MED/38 - Pediatria Generale E SpecialisticaJADAS Juvenile Idiopathic Arthritis disease activity
researchProduct

PARVOVIRUS INFECTION AND KAWASAKI DISEASE: ONE DISEASE FOR TWO SIBLINGS

2018

Introduction: Kawasaki disease (KD) is rarely described in siblings in the same time. In these cases, an infectious trigger must be excluded. Objectives: We describe the clinical course of two brothers who showed severe KD all at once, secondary to Parvovirus infection. Methods: A 9-month-old female showed fever, pallor, vomiting, bilateral non-secreting conjunctivitis, rash. Anamnesis revealed that 12 days before, she had fever, spontaneously resolved. At admission, 9 days after fever onset, she showed fever, conjunctivitis, pharyngitis, rash, and cervical adenopathy. Haematological parameters showed: leukocytosis, neutrophilia; anaemia; CRP: 2.31; ESR: 120. ECG and echocardiography were n…

Settore MED/38 - Pediatria Generale E SpecialisticaPARVOVIRUS INFECTION KAWASAKI DISEASE SIBLINGS
researchProduct

AUDITORY EVOKED POTENTIALS AND VISUAL EVOKED POTENTIALS: A HELPFUL TEST IN THE DIAGNOSIS AND FOLLOW UP OF KAWASAKI DISEASE

2018

Introduction: Kawasaki disease is a systemic vasculitis affecting mainly children; the most serious complications are coronary artery lesions (CAL). Nonetheless, the spectrum of complications involves all the vascular districts, such as the eyes, skin, kidneys, gallbladder, liver, central nervous system. Sensorineural hearing loss is a low diagnosed complication of KD, however, it may be permanent. Objectives: Auditory evoked potentials (ABR) and visual evoked potentials (VEPs) are useful in evaluating children without auditory and/or visual symptoms but with diseases that could sub clinically involve these functions. Methods: We enrolled 52 children (31 M, 21 F; age: 3 months-10 years) wit…

Settore MED/38 - Pediatria Generale E SpecialisticaAUDITORY EVOKED POTENTIALS VISUAL EVOKED POTENTIALS KAWASAKI DISEASE
researchProduct

Are Kawasaki Disease and Pediatric Multi-Inflammatory Syndrome Two Distinct Entities? Results from a Multicenter Survey During SARS-CoV-2 Epidemic in…

2020

Background: There is mounting evidence on the existence of a childhood multi-inflammatory syndrome related to SARS-CoV-2, sharing similarities with Kawasaki Disease (KD).  Methods: On April 24th,2020 the Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD or KD-like disease. Classification was: 1) classical and incomplete KD, named Kawasaki Disease Group (KDG); 2) KD-like multi-inflammatory syndrome, named KawaCOVID Group (KCG). Demographic, clinical, and laboratory data, treatment information, and patients’ outcome were collected in an online anonymized database (RedCAPO). Chi square test or exact Fisher test and non parametric W…

medicine.medical_specialtyMyocarditisHeart malformationbusiness.industryDiseasemedicine.diseaseInstitutional review boardsymbols.namesakeInternal medicineCohortChi-square testsymbolsMedicineKawasaki diseasebusinessFisher's exact testSSRN Electronic Journal
researchProduct

DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling.

2022

Background: Deoxyribonuclease 1 like 3 (DNASE1L3) is a secreted enzyme that has been shown to digest the extracellular chromatin derived from apoptotic bodies, and DNASE1L3 pathogenic variants have been associated with a lupus phenotype. It is unclear whether interferon signaling is sustained in DNASE1L3 deficiency in humans. Objectives: To explore interferon signaling in DNASE1L3 deficient patients. To depict the characteristic features of DNASE1L3 deficiencies in human. Methods: We identified, characterized, and analyzed five new patients carrying biallelic DNASE1L3 variations. Whole or targeted exome and/or Sanger sequencing was performed to detect pathogenic variations in five juvenile …

VasculitisEndodeoxyribonucleasesImmunologyDNAInflammatory Bowel DiseasesLupus NephritisChromatinANCA Apoptosis DNASE1L3 Interferon-stimulated genes Nucleic acids Systemic lupus erythematosus Type I interferonAntibodies Antineutrophil CytoplasmicSettore MED/38 - Pediatria Generale E SpecialisticaPhenotypeInterferon Type IImmunology and AllergyHumansLupus Erythematosus SystemicInterferonsJournal of clinical immunology
researchProduct

Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis.

2019

Introduction: The advent of biologic agents has revolutionized therapeutic approaches in systemic juvenile idiopatic arthritis (sJIA) as their introduction has been shown to modify disease course and improve overall outcomes, particularly when initiated early. Few studies have reported the drug retention rate (DRR) of biologic drugs in JIA, and none of them has specifically investigated the DRR of interleukin (IL)-1 inhibitors on sJIA. Objectives: The primary aim of the study was to examine the overall DRR of IL-1 blockers in sJIA patients. Secondary aims of our study were to: (i) explore the influence of biologic line of treatment, adverse events (AEs), type of anti-IL-1 agent and the conc…

0301 basic medicineDrugmedicine.medical_specialtysystemic juvenile idiopathic arthritismedia_common.quotation_subjectArthritisanakinra; canakinumab; drug retention rate; interleukin 1-beta; systemic juvenile idiopathic arthritis; therapycanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInterleukin-1 inhibitors Systemic Juvenile Idiopathic Arthritis Anakinra CanakinumabInternal medicineinterleukin 1-betaMedicinePharmacology (medical)Adverse effectmedia_commonOriginal ResearchPharmacologyAnakinraAnakinra Canakinumab Drug retention rate Interleukin 1-beta Systemic juvenile idiopathic arthritis Therapytherapybusiness.industrylcsh:RM1-950Hazard ratioInterleukinJuvenile idiopathic arthritisRetention ratemedicine.diseaseCanakinumablcsh:Therapeutics. Pharmacology030104 developmental biology030220 oncology & carcinogenesisSystemic juvenile idiopathic arthritidrug retention ratebusinessmedicine.druganakinraFrontiers in pharmacology
researchProduct

ASSESSING THE CLINICAL RELEVANCE AND RISK MINIMIZATION OF ANTIBODIES TO BIOLOGICS IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) (ABIRISK) - PRELIMINARY RESU…

2018

Introduction: ABIRISK is a project funded by Innovative Medicine Initiative, with the aim to investigate anti-drug antibody (ADA) formation in the treatment of JIA with biologics (BPs). A major limitation to the use of biologics is the development of ADA that may decrease the efficacy of BPs. Objectives: The aim of this project is to improve the capability to predict biologic immunogenicity in JIA patients. Methods: JIA Patients (by ILAR criteria) followed by 24 PRINTO centres in 12 countries were prospectively enrolled and treated with Etanercept, Adalimumab or Tocilizumab. Patient’s data were obtained from Pharmachild, a pharmacovigilance data registry of JIA patients. For each patient de…

Settore MED/38 - Pediatria Generale E SpecialisticaJIA ABIRISK
researchProduct

Additional file 2 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 2: Appendix 2. Clinical comparison between Kawasaki Disease patients seen during SARS-CoV-2 epidemic and a Historical Cohort of Kawasaki Disease Patients.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

A national cohort study on pediatric Behçet's disease: Cross-sectional data from an Italian registry

2017

Abstract Background Behçet’s disease is a rare multi-systemic inflammatory disease with unknown etiology which involves principally oral and genital mucosa, skin and eyes. Average age at onset of the disease is about 25-30 years, but it may be diagnosed before the age of 16. It is not very rare in Italy, even though there are limited data concerning epidemiology. Aim of this study is to describe the baseline data of an Italian cohort of patients with as having BD or probable BD. Methods We described the baseline data of the first national epidemiological study on children coming from 16 Italian Pediatric Rheumatologic Centers diagnosed by the treating physicians as having Behçet’s Disease. …

Malelcsh:Diseases of the musculoskeletal systemDiagnostic criteriaCross-sectional studyConstitutional symptomsBehcet's diseasePediatricsCohort StudiesBehçet’s diseaseBiological Factors0302 clinical medicineEpidemiologyImmunology and AllergyLongitudinal StudiesRegistries030212 general & internal medicineBehçet’s disease Children Clinical features Diagnostic criteria Treatment Pediatrics Perinatology and Child Health Rheumatology Immunology and AllergyChildChildrenBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Adolescent; Behcet Syndrome; Biological Factors; Child; Cohort Studies; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Italy; Longitudinal Studies; Male; Registries; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergyeducation.field_of_studyBehçet's diseaseBehcet Syndromelcsh:RJ1-570Perinatology and Child HealthItalySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACohortFemaleImmunosuppressive AgentsResearch ArticleCohort studyBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and Allergymedicine.medical_specialtyAdolescentPopulationBehçet's disease03 medical and health sciencesRheumatologyInternal medicinemedicineHumansBehçet's disease; Children; Clinical features; Diagnostic criteria; Treatment; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyeducationGlucocorticoids030203 arthritis & rheumatologybusiness.industrylcsh:PediatricsClinical featuresmedicine.diseaseTreatmentCross-Sectional StudiesClinical featurePediatrics Perinatology and Child HealthEtiologylcsh:RC925-935business
researchProduct

Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports

2017

Abstract Background Anti-N-methyl-D-aspartate receptor encephalitis is a rare autoimmune disease characterized by severe neurological and psychiatric symptoms and a difficult diagnosis. The disease is often secondary to a neoplastic lesion, seldom diagnosed years later. Psychiatric symptoms are prevalent in adults; neurologic symptoms are more evident in children, who typically present primarily with neurological symptoms. To the best of our knowledge, the association with juvenile idiopathic arthritis has not been described. Case presentation We report the cases of two caucasian girls with an atypical presentation. The first patient was an 8-year-old girl with normal psychomotor developmen…

PediatricsPathologyChoreiform movementAnti-Inflammatory AgentsArthritislcsh:MedicineCase ReportDisease0302 clinical medicinePrednisoneChildOvarian Neoplasms030219 obstetrics & reproductive medicineMedicine (all)Remission InductionTeratomaImmunoglobulins IntravenousGeneral MedicineMagnetic Resonance ImagingTreatment OutcomeMethylprednisoloneFemaleHip JointTeratomamedicine.symptomEncephalitismedicine.drugmedicine.medical_specialtyAdolescentAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Medicine (all)Methylprednisolone03 medical and health sciencesJuvenile idiopathic arthritiChoreaPsychiatric symptomsmedicineHumansImmunologic FactorsAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; TeratomaAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Adolescent; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Arthritis Infectious; Child; Female; Hip Joint; Humans; Immunoglobulins Intravenous; Immunologic Factors; Magnetic Resonance Imaging; Methylprednisolone; Ovarian Neoplasms; Remission Induction; Teratoma; Treatment Outcome; Medicine (all)Speech disorderSpeech disordersArthritis InfectiousPsychiatric symptombusiness.industrylcsh:RChoreaJuvenile idiopathic arthritismedicine.diseaseAnti-N-methyl-D-aspartate receptor encephalitisbusiness030217 neurology & neurosurgeryAnti-N-methyl-D-aspartate receptor encephaliti
researchProduct

Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling.

2014

The type I interferon system is integral to human antiviral immunity. However, inappropriate stimulation or defective negative regulation of this system can lead to inflammatory disease. We sought to determine the molecular basis of genetically uncharacterized cases of the type I interferonopathy Aicardi-Goutières syndrome, and of other patients with undefined neurological and immunological phenotypes also demonstrating an upregulated type I interferon response. We found that heterozygous mutations in the cytosolic double-stranded RNA receptor gene IFIH1 (MDA5) cause a spectrum of neuro-immunological features consistently associated with an enhanced interferon state. Cellular and biochemica…

Models MolecularInterferon-Induced Helicase IFIH1Molecular Sequence DataHDE NEU PEDElectrophoretic Mobility Shift AssayBiologymedicine.disease_causeNervous System MalformationsReal-Time Polymerase Chain ReactionArticleDEAD-box RNA HelicasesImmune systemAutoimmune Diseases of the Nervous SystemDownregulation and upregulationAnalysis of Variance; Autoimmune Diseases of the Nervous System; Base Sequence; DEAD-box RNA Helicases; Electrophoretic Mobility Shift Assay; Exome; HEK293 Cells; Humans; Interferon Type I; Microsatellite Repeats; Molecular Sequence Data; Mutation; Nervous System Malformations; Real-Time Polymerase Chain Reaction; Sequence Analysis DNA; Signal Transduction; Spectrum Analysis; Models Molecular; Phenotype; GeneticsModelsInterferonGeneticsmedicineHumansExomeMutationAnalysis of VarianceBase SequenceSpectrum AnalysisMolecularRNAMDA5DNASequence Analysis DNAMolecular biology3. Good healthInterferon Tipo IHEK293 CellsPhenotypeInterferon Type IMutationCancer researchSignal transductionSequence AnalysisInterferon type Imedicine.drugMicrosatellite RepeatsSignal TransductionNature genetics
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

2018

The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Italian language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their paren…

GerontologyMaleParentsPatient Reported Outcome MeasurePsychometricsHealth StatusArthritisJuvenilePredictive Value of TestHealth StatuDisability Evaluation0302 clinical medicineMedicineImmunology and AllergyFunctional abilityAge of OnsetChildJAMARPatientPrognosisDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Adolescent; Age of Onset; Arthritis Juvenile; Case-Control Studies; Child; Child Preschool; Cultural Characteristics; Female; Health Status; Humans; Italy; Male; Parents; Patients; Predictive Value of Tests; Prognosis; Psychometrics; Quality of Life; Reproducibility of Results; Rheumatology; Translating; Disability Evaluation; Patient Reported Outcome MeasuresCultural CharacteristicSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyChild PreschoolPredictive value of testsFemaleCase-Control StudiePsychometricHumanmedicine.medical_specialtyDisease statusAdolescentPatientsPsychometricsPrognosiImmunologyReproducibility of ResultDisease status; Functional ability; Health Related Quality of Life; JAMAR; Juvenile idiopathic arthritis; Rheumatology; Immunology and Allergy; Immunology03 medical and health sciencesJuvenile idiopathic arthritiQuality of life (healthcare)RheumatologyDisease status Functional ability Health Related Quality of Life JAMAR Juvenile idiopathic arthritis Adolescent Age of Onset Arthritis Juvenile Case-Control Studies Child Child Preschool Cultural Characteristics Female Health Status Humans Italy Male Parents Patients Predictive Value of Tests Prognosis Psychometrics Quality of Life Reproducibility of Results Rheumatology Translating Disability Evaluation Patient Reported Outcome MeasuresPredictive Value of Tests030225 pediatricsInternal medicineJuvenileHumansValidation StudiesPatient Reported Outcome MeasuresDisease statuPreschool030203 arthritis & rheumatologyCultural Characteristicsbusiness.industryArthritisReproducibility of ResultsHealth Related Quality of LifeTranslatingJuvenile idiopathic arthritismedicine.diseaseFunctional abilityArthritis JuvenileRheumatologyParentCase-Control StudiesQuality of LifeAge of onsetbusiness
researchProduct

Systemic lupus erythematosus and bullous pemphigoid with dramatic response to dapsone

2017

Patient: Female, 11 Final Diagnosis: Bullous pemphigoid in systemic lupus erythematosus Symptoms: Bullous lupus • photosensitive rash • synovitis Medication:— Clinical Procedure: Pharmacological treatment Specialty: Rheumatology Objective: Unusual clinical course Background: Bullous pemphigoid is an autoimmune blistering disease, with relapses, isolated or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Joint manifestations rapidly respond to small or moderate doses of corticosteroids, whereas skin manifestations usually respond to antimalarial drugs. Case Report: We describe the clinical case of an 11-year-old girl with SLE. She showed bullous skin les…

Pemphigoidmedicine.medical_specialtyAntimalarials; Child; Dapsone; Female; Humans; Lupus Erythematosus Systemic; Pemphigoid BullousMild proteinuriaArthritisDapsoneAntimalarials030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaPrednisoneimmune system diseasesPemphigoid BullousmedicineHumansChildskin and connective tissue diseases030203 arthritis & rheumatologyLupus erythematosusintegumentary systembusiness.industryMedicine (all)Dapsone; Lupus erythematosus systemic; Pemphigoid bullous; Medicine (all)ArticlesGeneral Medicinemedicine.diseasePemphigoid bullouDermatologyeye diseasesLupus erythematosus systemicFemaleBullous pemphigoidsense organsbusinessDapsonemedicine.drugPediatric population
researchProduct

Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis

2009

Abstract Background Undiagnosed patients with the attenuated form of mucopolysaccharidosis (MPS) type I often have joint symptoms in childhood that prompt referral to a rheumatologist. A survey conducted by Genzyme Corporation of 60 European and Canadian rheumatologists and pediatric rheumatologists demonstrated that Bone and joint manifestations are prominent among most patients with MPS disorders. These life-threatening lysosomal storage diseases are caused by deficient activity of specific enzymes involved in the degradation of glycosaminoglycans. Patients with attenuated MPS disease often experience diagnostic delays. Enzyme replacement therapy is now commercially available for MPS I (l…

musculoskeletal diseasesmedicine.medical_specialtyPediatricscongenital hereditary and neonatal diseases and abnormalitieslcsh:Diseases of the musculoskeletal systemIdursulfaseMucopolysaccharidosisDiseaseRheumatologyInternal medicinemedicineImmunology and AllergyPediatrics Perinatology and Child HealthYoung adultCarpal tunnel syndromeskin and connective tissue diseasesbusiness.industrylcsh:RJ1-570nutritional and metabolic diseaseslcsh:PediatricsEnzyme replacement therapyHypothesismedicine.diseaseRheumatologyJoint painPediatrics Perinatology and Child Healthmedicine.symptomlcsh:RC925-935businessmedicine.drugPediatric Rheumatology
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Brainstem Auditory Evoked Potentials and Visual Potentials in Kawasaki Disease: An Observational Monocentric Study

2020

Background: Kawasaki Disease is a systemic vasculitis, particularly involving coronary arteries. Rare involvement of other vascular districts is described, as central nervous system arteries, leading to a vasculitic neuropathy. Sensorineural hearing loss and alterations of evoked potentials are uncommonly reported complications.Methods: In an observational monocentric study, 59 children (37 males; 22 females; mean age: 2.7 ± 2.2 years) with documented Kawasaki Disease were enrolled. No risk factors for hearing loss and/or neurological impairment were identified in the cohort. Brainstem auditory evoked potentials and visual evoked potentials were correlated with clinical, hamatological and r…

medicine.medical_specialtygenetic structuresHearing lossvisual evoked potentialsCentral nervous systemintravenous immunoglobulinscoronary artery lesionPediatrics03 medical and health sciences0302 clinical medicine030225 pediatricsInternal medicineintravenous immunoglobulinmedicinekawasaki diseasePathologicalOriginal Researchbusiness.industrylcsh:RJ1-570lcsh:Pediatricscoronary artery lesionsmedicine.diseaseCoronary arteriesmedicine.anatomical_structurePediatrics Perinatology and Child Healthbrainstem auditory evoked potentialCardiologyKawasaki diseaseSensorineural hearing lossBrainstemmedicine.symptomvisual evoked potentialbusinessbrainstem auditory evoked potentials030217 neurology & neurosurgeryArteryFrontiers in Pediatrics
researchProduct

Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting Abstracts
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct

Additional file 1 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 1: Appendix 1.

researchProduct

Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor—Associated Periodic Syndrome (TRAPS): A S…

2020

This study explores demographic, clinical, and therapeutic features of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a cohort of 80 patients recruited from 19 Italian referral Centers. Patients’ data were collected retrospectively and then analyzed according to age groups (disease onset before or after 16 years) and genotype (high penetrance (HP) and low penetrance (LP) TNFRSF1A gene variants). Pediatric- and adult-onset were reported, respectively, in 44 and 36 patients; HP and LP variants were found, respectively, in 32 and 44 cases. A positive family history for recurrent fever was reported more frequently in the pediatric group than in the adult group (p<0.05…

0301 basic medicinemyalgiaMaleAbdominal painSettore MED/16 - REUMATOLOGIATNFRSF1AGene mutationGastroenterology0302 clinical medicinePathologyMedicineRB1-214PericarditisChildPrognosisPenetranceInflamacióFamilial Mediterranean FeverAIDA networkEstudi de casosReceptors Tumor Necrosis Factor Type IChild PreschoolAutoinflammationFemalemedicine.symptomResearch ArticleAdultmedicine.medical_specialtyArticle SubjectAdolescentGenotypetumor necrosis factorImmunologyContext (language use)Asymptomatic03 medical and health sciencesYoung AdultInternal medicineAnimalsHumansRetrospective Studies030203 arthritis & rheumatologyInflammationbusiness.industrytumor necrosis factor TRAPS AIDA networkTumor Necrosis Factor-alphaInfantTRAPSCell BiologyMyalgiaBiological productmedicine.disease030104 developmental biologyMutationCase studiesbusinessKidney diseaseMediators of Inflammation
researchProduct

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

2016

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…

MaleBiologic therapieBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyArthritisJuvenilePediatricsInflammatory bowel diseaseEtanerceptEtanerceptTNF inhibitorsSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineQuality of lifeRetrospective StudieImmunology and AllergyPediatric rheumatology030212 general & internal medicineChildBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyDrug SubstitutionBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyAntirheumatic AgentPerinatology and Child Health3. Good healthTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAntirheumatic AgentsFemaleResearch ArticleHumanmedicine.drugBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcomemedicine.medical_specialtyAdolescent03 medical and health sciencesJuvenile idiopathic arthritiRheumatologyInternal medicineBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitorsmedicineHumansPediatrics Perinatology and Child HealthAdverse effectPreschoolRetrospective StudiesCross-Sectional Studie030203 arthritis & rheumatologybusiness.industryArthritisRetrospective cohort studyJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileRheumatologyDiscontinuationPatient Outcome AssessmentBiologic therapiesCross-Sectional StudiesMethotrexatePediatrics Perinatology and Child HealthPhysical therapybusinessTNF inhibitor
researchProduct

Increased Percentages of Tumor Necrosis Factor-α+/Interferon-T+Lymphocytes and Calprotectin+/Tumor Necrosis Factor-A+ Monocytes in Patients with Acut…

2012

In vivo exposure to microorganisms resident in the oral cavity is considered as a possible cause of Kawasaki disease (KD), and some epitopes derived from streptococci display homology with Factor H of Complement. Additionally, calprotectin, a major calcium binding protein released by neutrophils and activated monocytes, could be directly involved in endothelial damage occurring in KD. The aim of our study is to evaluate the percentages of IFN-γ+ and/or TNF-α+ lymphocytes and double positive calprotectin/TNF-α monocytes (CD14+) after in vitro stimulation with streptococcal- and/or Factor H-derived peptides, in patients with acute KD. Peripheral Blood Mononuclear Cells (PBMCs) obtained from …

Pharmacologybusiness.industryImmunologymedicine.diseaseEpitopeInterferonIn vivoImmunologymedicineImmunology and AllergyIn patientKawasaki diseaseTumor necrosis factor alphaCalprotectinbusinessTumor necrosis factor αmedicine.drugInternational Journal of Immunopathology and Pharmacology
researchProduct

Kawasaki disease in Sicily: clinical description and markers of disease severity

2016

Background: Kawasaki disease (KD) is an acute systemic vasculitis of small and middle size arteries; 15-25 % of untreated patients and 5 % of patients treated with intravenous immunoglobulin (IVIG) develop coronary artery lesions (CAL). Many studies tried to find the most effective treatment in the management of resistant KD and to select the risk factors for CAL. Our data are assessed on children from west Sicily, characterized by a genetic heterogeneity. Methods: We studied the clinical data of 70 KD Sicilian children (36 males: 51 %; 34 females: 49 %), analysed retrospectively, including: demographic and laboratory parameters; echocardiographic findings at diagnosis, at 2, 6 and 8 weeks,…

VasculitisMaleVasculitimedicine.medical_specialtyCardiovascular Disease; Kawasaki Disease; Small Vessel Vasculitis; Vasculitis030204 cardiovascular system & hematologyMucocutaneous Lymph Node SyndromeSeverity of Illness IndexSmall Vessel Vasculitis03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineDisease severity030225 pediatricshemic and lymphatic diseasesCardiovascular DiseaseMedicineEffective treatmentHumansKawasaki DiseaseSicilyCardiovascular Disease; Kawasaki Disease; Small Vessel Vasculitis; Vasculitis; Pediatrics Perinatology and Child HealthRetrospective Studiesbiologybusiness.industryGenetic heterogeneityResearchmedicine.diseaseDermatologySmall Vessel Vasculitimedicine.anatomical_structureEchocardiographyChild PreschoolPediatrics Perinatology and Child HealthImmunologybiology.proteinKawasaki diseaseFemaleAntibodybusinessVasculitisBiomarkersSystemic vasculitisArteryItalian Journal of Pediatrics
researchProduct

Transitional care of young people with juvenile idiopathic arthritis in Italy: results of a Delphi consensus survey

2018

OBJECTIVES: To present the results of a Delphi consensus survey among Italian paediatric and adult rheumatologists on transitional care (TC) of young people (YP) with juvenile idiopathic arthritis (JIA). METHODS: A taskforce of 27 paediatric and adult rheumatologists evaluated the applicability of the 2016 EULAR/PReS recommendations for TC to the Italian rheumatology practice and healthcare system and formulated additional country-specific statements aimed to increase their suitability. After a two-round discussion, applicability of EULAR/PReS recommendations and agreement with newly-proposed statements were voted on a 0-10 scale (where 0 = no applicability/agreement and 10 = total applicab…

AdultTransition to Adult CareSettore MED/16 - REUMATOLOGIApaediatric rheumatic diseasesConsensusAdolescentJuvenileSocio-culturaleAdolescent; Adult; Child; Consensus; Humans; Italy; Surveys and Questionnaires; Arthritis Juvenile; Rheumatology; Transition to Adult Care; Transitional Carejuvenile idiopathic arthritis paediatric rheumatic diseases Delphi survey recommendations transitional care young peopleAdolescent Adult Child Consensus Humans Italy Surveys and Questionnaires Arthritis Juvenile Rheumatology Transition to Adult Care Transitional Careyoung peopleSettore MED/38 - Pediatria Generale E Specialisticayoung peopleAdolescentRheumatologySurveys and QuestionnairesHumansChildLS7_9ArthritisTransitional CareArthritis JuvenileItalyrecommendationsjuvenile idiopathic arthritisDelphi surveyjuvenile idiopathic arthritis paediatric rheumatic diseases Delphi survey recommendations transitional care young people
researchProduct

Anti-IL1 in patients with low penetrance mutations for autoinflammatory diseases: tuscany and sicilian case series from paediatric to adult age

2017

Patients with low penetrance mutations for Autoinflammatory syndromes (AID) can have severe clinical manifestations, which require to be treated with biological drugs anti-IL-1. Objectives: To evaluate the response of AID to treatment with the recombinant human IL-1 receptor antagonist anakinra or with the anti-IL-1b.

Settore MED/38 - Pediatria Generale E SpecialisticaAutoinflammatory syndromes anti-IL-1 IL-1
researchProduct

Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings.

2019

Abstract Background There are reports of the familial occurrence of Kawasaki disease but only a few reports described Kawasaki disease in siblings. However, the familial cases were not simultaneous. In these patients the idea of infective agents as trigger must be considered. Case presentation We describe two siblings with atypical presentations of Kawasaki disease; the sister was first diagnosed as having parvovirus infection with anemia and the brother was diagnosed as having myocarditis. The first patient was a 9-month-old Caucasian girl with fever, conjunctivitis, rash, and pharyngitis, and later she had cervical adenopathy, diarrhea and vomiting, leukocytosis, and anemia, which were ex…

Malemedicine.medical_specialtyAbdominal painViral MyocarditisMyocarditisCardiotonic AgentsDopaminelcsh:MedicineCase Report030204 cardiovascular system & hematologyGastroenterologyParvoviridae InfectionsParvovirus03 medical and health sciences0302 clinical medicineInternal medicineDobutaminemedicineHumansImmunologic FactorsLeukocytosisChildKawasaki diseasebusiness.industryMedicine (all)Siblingslcsh:RParvovirus infectionCoronary AneurysmInfantShockStroke VolumeGeneral MedicineKawasaki shock syndromemedicine.diseasePharyngitisInterleukin 1 Receptor Antagonist ProteinTreatment OutcomeAnakinraEchocardiography030220 oncology & carcinogenesisAnuriaKawasaki diseaseFemalemedicine.symptombusinessImmunosuppressive AgentsJournal of medical case reports
researchProduct

American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic L…

2019

OBJECTIVE: To develop a Childhood Lupus Improvement Index (CHILI) as a tool to measure response to therapy in childhood-onset systemic lupus erythematosus (cSLE), with a focus on clinically relevant improvement (CRIc SLE ). METHODS: Pediatric nephrology and rheumatology subspecialists (n = 213) experienced in cSLE management were invited to define CRIc SLE and rate a total of 433 unique patient profiles for the presence/absence of CRIc SLE . Patient profiles included the following cSLE core response variables (CRVs): global assessment of patient well-being (patient-global), physician assessment of cSLE activity (MD-global), disease activity index score (here, we used the Systemic Lupus Eryt…

medicine.medical_specialtyOutcome AssessmentHealth Care/methodsAdolescentDelphi TechniqueAntirheumatic Agents/therapeutic useSeverity of Illness IndexChild healthArticle03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineSeverity of illnessOutcome Assessment Health CaremedicinePediatric nephrologyHumansLupus Erythematosus Systemicskin and connective tissue diseasesChild030203 arthritis & rheumatologySystemic lupus erythematosusLupus erythematosusLupus ErythematosusReceiver operating characteristicbusiness.industryConsensus conferencechildhood-onset systemic lupus erythematosusOutcome Assessment Health Care/methodsmedicine.diseaseRheumatologyRheumatologySystemic lupus erythematosusautoimmune inflammatory diseaseAntirheumatic AgentsLupus Erythematosus Systemic/drug therapySystemic/drug therapybusinessAlgorithmsArthritis Care and Research
researchProduct

Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

2019

Made available in DSpace on 2019-10-05T16:54:20Z (GMT). No. of bitstreams: 0 Previous issue date: 2019-04-01 IRCCS Istituto Giannina Gaslini Background To our knowledge, the characteristics and burden of childhood arthritis have never been studied on a worldwide basis. We aimed to investigate, with a cross-sectional study, the prevalence of disease categories, treatment methods, and disease status in patients from across different geographical areas and from countries with diverse wealth status. Methods In this multinational, cross-sectional, observational cohort study, we asked international paediatric rheumatologists from specialised centres to enrol children with a diagnosis of juvenile …

Malemedicine.medical_specialtyChildhood arthritisCross-sectional studyPopulationGlobal HealthPediatrics03 medical and health sciences0302 clinical medicine030225 pediatricsEpidemiologymedicineDevelopmental and Educational PsychologyJournal ArticleHumansPediatrics Perinatology and Child Health; Developmental and Educational Psychology030212 general & internal medicineHealthcare DisparitiesChildeducationDisease burdenPain MeasurementRetrospective Studieseducation.field_of_studyOligoarthritisbusiness.industryPerinatology and Child HealthJuvenile idiopathic arthritismedicine.diseaseJUVENILE IDIOPATHIC ARTHRITIS; OF-RHEUMATOLOGY RECOMMENDATIONS; DISEASE-ACTIVITY SCORE; DEFINING CRITERIA; CLASSIFICATION; CHILDREN; EPIDEMIOLOGY; VALIDATION; COUNTRIES; VALIDITYArthritis Juvenilechildhood arthritisphenotypic variabilityobservational cohort studyCross-Sectional StudiesBiological Variation PopulationSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAAntirheumatic AgentsChild PreschoolPediatrics Perinatology and Child HealthQuality of LifeFemalePolyarthritisJuvenile idiopatic arthritis of-rheumatology recommentadions disease-activity score defining criteria classification children epidemiology validation countries validitybusinessDemographyCohort study
researchProduct

Metabolic bone disease and osteoporosis in children

2016

To understand the basics of pediatric bone metabolism and mechanisms underlying osteoporosis.

Settore MED/38 - Pediatria Generale E SpecialisticaOsteogenesis imperfectabusiness.industryMedicine (all)OsteoporosisTurner syndromemedicinemedicine.diseasebusinessBioinformaticsMetabolic bone diseaseBone remodeling
researchProduct

Additional file 4 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 4: Appendix 4. Clinical comparison between Kawasaki Disease patients seen during SARS-CoV-2 in high epidemic regions (Piedmont and Lombardy) and Kawasaki Disease Patients in low epidemic regions.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

Development and initial validation of the macrophage activation syndrome/primary hemophagocytic lymphohistiocytosis score, a diagnostic tool that dif…

2017

OBJECTIVE: To develop and validate a diagnostic score that assists in discriminating primary hemophagocytic lymphohistiocytosis (pHLH) from macrophage activation syndrome (MAS) related to systemic juvenile idiopathic arthritis. STUDY DESIGN: The clinical, laboratory, and histopathologic features of 362 patients with MAS and 258 patients with pHLH were collected in a multinational collaborative study. Eighty percent of the population was assessed to develop the score and the remaining 20% constituted the validation sample. Variables that entered the best fitted model of logistic regression were assigned a score, based on their statistical weight. The MAS/HLH (MH) score was made up with the i…

Male0301 basic medicineHemophagocyticLogistic regressionPediatricshemophagocytic syndrome0302 clinical medicine*diagnostic scoreDiagnosisMedicineCutoffChildprimary hemophagocytic lymphohistiocytosiLymphohistiocytosiseducation.field_of_studyprimary hemophagocytic lymphohistiocytosisPerinatology and Child Healthdiagnostic scoreQuartileSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAMacrophage activation syndromeChild Preschool*macrophage activation syndromeAbsolute neutrophil countFemale*primary hemophagocytic lymphohistiocytosisHumanmedicine.medical_specialtyAdolescentPopulationLymphohistiocytosis HemophagocyticDiagnosis Differential03 medical and health sciencesInternal medicineHumansPreschooleducation030203 arthritis & rheumatologyReceiver operating characteristicbusiness.industryInfantReproducibility of Resultsmedicine.diseaseSurgery030104 developmental biologydiagnostic score; hemophagocytic syndrome; macrophage activation syndrome; primary hemophagocytic lymphohistiocytosis; Adolescent; Child; Child Preschool; Diagnosis Differential; Female; Humans; Infant; Lymphohistiocytosis Hemophagocytic; Macrophage Activation Syndrome; Male; Reproducibility of Results; Pediatrics Perinatology and Child HealthMacrophage activation syndromeDifferentialPediatrics Perinatology and Child Health*hemophagocytic syndromeDifferential diagnosisbusiness
researchProduct

Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients

2014

The advent of biologic medications has considerably increased the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients.

juvenile idiopathic arthritis etanerceptmedicine.medical_specialtyPediatricsbusiness.industryAlternative medicineArthritismedicine.diseaseRheumatologyEtanerceptDisease courseSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicinePoster PresentationPediatrics Perinatology and Child HealthPhysical therapymedicineImmunology and AllergyJuvenilePediatrics Perinatology and Child Healthbusinessmedicine.drug
researchProduct

Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis

2020

Made available in DSpace on 2021-06-25T10:38:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2020-11-01 Healthway Objective. To develop a composite disease activity score for systemic JIA (sJIA) and to provide preliminary evidence of its validity. Methods. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) was constructed by adding to the four items of the original JADAS a fifth item that aimed to quantify the activity of systemic features. Validation analyses were conducted on patients with definite or probable/possible sJIA enrolled at first visit or at the time of a flare, who had active systemic manifestations, which should include fever. Patients were reassessed 2 wee…

MaleClinical assessment; Composite disease activity score; Disease activity; Outcome measures; Pediatric rheumatology; Still's disease; Systemic juvenile idiopathic arthritismedicine.medical_specialtyFeverClinical assessmentComposite disease activity scoreArthritisLymphadenopathyDiseaseSeverity of Illness IndexOutcome measuresOutcome measureJuvenile Arthritis Disease Activity ScoreRheumatologyCronbach's alphaSystemic juvenile idiopathic arthritisInternal medicineStill's diseaseContent validityMedicineJuvenileHumansPharmacology (medical)Pediatric rheumatologyDisease activityRange of Motion ArticularChildPain MeasurementSerositisThrombocytosisbusiness.industryConstruct validityReproducibility of ResultsAnemiaExanthemamedicine.diseaseArthralgiaRheumatologyArthritis JuvenileChild PreschoolSplenomegalyQuality of LifeFemaleHyperferritinemiabusinessHepatomegaly
researchProduct

Additional file 5 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 5: Appendix 5. Comparison of laboratory tests between Kawasaki Disease patients seen during SARS-CoV-2 in high epidemic regions (Piedmont and Lombardy) and Kawasaki Disease Patients in low epidemic regions.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

Increased percentages of calprotectin and TNF-Α double-positive monocytes in the acute phase of Kawasaki disease

2011

Background The acute phase of KD is characterized by a deficiency of suppressor T cells, marked activation of the immune system and increased secretion of cytokines by immune effector cells. Moreover, it has been shown that myeloid-related protein (MRP-8 and MRP-14) and S100proteins, the major calcium-binding proteins secreted by activated neutrophils and monocytes, contribute to cause inflammation in acute lesions of KD, and indeed one of the more common hematological alteration in KD is the increase of peripheral blood monocytes. Calprotectin, one of the major calcium-binding proteins, can lead to direct and indirect effects that result not only in inflammation but also in modification of…

Pediatricsmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemDouble negativeInflammationTNF alfa CalprotectinImmune systemSettore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineImmunology and AllergyMedicineSecretionPediatrics Perinatology and Child HealthKawasaki Diseasebusiness.industrylcsh:RJ1-570lcsh:Pediatricsmedicine.diseaseRheumatologyPediatrics Perinatology and Child HealthImmunologyOral PresentationKawasaki diseaselcsh:RC925-935Calprotectinmedicine.symptombusinessVasculitisPediatric Rheumatology Online Journal
researchProduct

Acute rheumatic fever prophylaxis in high-income countries: clinical observations from an Italian multicentre, retrospective study.

2019

Objective-The aim of the study is to evaluate the compliance rate to secondary prophylaxis and the presence of Rheumatic Heart Disease (RHD) in a cohort of Italian patients with Acute Rheumatic Fever (ARF). Methods-This is a multicentre retrospective study. Patients were divided into two groups according to the presence or absence at last follow-up of RHD. Clinical features, ARF recurrences and the rate of compliance to secondary prophylaxis were evaluated. Results-wo hundred and ninety patients were enrolled (137 females, 153 males). Carditis at onset was present in 244 patients (84.7%). At the end of follow-up, 173 patients showed RHD. Adherence to secondary prophylaxis was low in 26% of …

MaleprophylaxiDeveloped CountriesRheumatic Heart Diseaseacute rheumatic fever; prophylaxis; rheumatic heart diseaseCarditirheumatic heart diseaseAcute rheumatic feveracute rheumatic feverSettore MED/38 - Pediatria Generale E SpecialisticaItalyHumansFemaleprophylaxisProphylaxiRheumatic FeverAcute rheumatic fever Carditis Compliance Prophylaxis Rheumatic heart diseaseComplianceRetrospective StudiesClinical and experimental rheumatology
researchProduct

THE USE OF INTERLEUKIN 1 RECEPTOR ANTAGONIST (ANAKINRA) IN KAWASAKI DISEASE: A RETROSPECTIVE CASES SERIES

2018

Introduction: Persistent fever and inflammation after infusion of 2g/kg of IVIG, the standard treatment of KD represents a high-risk situation for coronary aneurysms in Kawasaki disease. Identifying patients at risk for IVIG resistance is difficult outside the Asian population, and there remains a critical unmet need to identify an anti-inflammatory treatment that is efficacious in all KD patients. Recent evidence from studies in animals and humans suggest a critical role for interleukin-1 (IL-1) α and β in the pathogenesis of KD. Objectives: To identify the clinical characteristics, reasons for use and response to treatment with anakinra in a retrospective series of patients with Kawasaki …

Male0301 basic medicineBLOCKADEPlacebo-controlled studyCHILDRENSUSCEPTIBILITYPLACEBO-CONTROLLED TRIALPediatricsDOUBLE-BLIND0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieINTERLEUKIN 1 RECEPTOR ANTAGONIST ANAKINRA KAWASAKI DISEASEImmunology and AllergyJUVENILE IDIOPATHIC ARTHRITISChildPediatricAnakinra coronary artery aneurysmPrognosis1107 ImmunologyChild PreschoolDisease ProgressionFemaleVasculitisLife Sciences & BiomedicineHumanmedicine.drugVasculitismusculoskeletal diseasesAutoinflammatory diseaseVasculitimedicine.medical_specialtyMyocarditisPrognosiImmunologyMucocutaneous Lymph Node SyndromeAnakinra coronary artery aneurysms03 medical and health sciencesInternal medicineINFLIXIMABMANAGEMENTmedicineINTRAVENOUS IMMUNOGLOBULINHumansRetrospective Studies030203 arthritis & rheumatologyAnakinraScience & TechnologyKawasaki diseasebusiness.industryInfantReceptors Interleukin-1Retrospective cohort studymedicine.diseaseInfliximabInterleukin 1 Receptor Antagonist Protein030104 developmental biologyInterleukin 1 receptor antagonistKawasaki diseasebusinessInterleukin-1
researchProduct

Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part three

2017

lcsh:Diseases of the musculoskeletal systemlcsh:RJ1-570lcsh:Pediatricslcsh:RC925-935Meeting AbstractsPediatric Rheumatology Online Journal
researchProduct

Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease

2021

AbstractAim of these revised recommendations for the general management of Kawasaki disease is to encourage its prompter recognition and warrant the most appropriate therapy, based on ascertained scientific data, raising awareness of the complications related to misdiagnosis or delayed treatment. A set of 20 synthetic operative statements is herein provided, including the definition of Kawasaki disease, its protean presentations, clinical course and seminal treatment modalities of all disease phases. The application of these recommendations should improve prognosis of Kawasaki disease and prevent the progression to permanent vascular abnormalities, thereby diminishing morbidity and mortalit…

Pediatricsmedicine.medical_specialty2019-20 coronavirus outbreakAspirin; Children; Coronary artery abnormalities; Intravenous immunoglobulin; Kawasaki diseaseReview030204 cardiovascular system & hematologyMucocutaneous Lymph Node SyndromeDiagnosis Differential03 medical and health sciences0302 clinical medicine030225 pediatricshemic and lymphatic diseasesmedicineHumansChildCoronary artery abnormalitieChildrenIntravenous immunoglobulinAspirinAspirinKawasaki diseasebusiness.industryClinical courselcsh:RJ1-570Immunoglobulins Intravenouslcsh:PediatricsGeneral MedicineDelayed treatmentmedicine.diseasePrognosisSettore MED/38Disease phasesSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAEl NiñoItalyTreatment modalityDisease ProgressionAspirin Children Coronary artery abnormalities Intravenous immunoglobulin Kawasaki diseaseKawasaki diseasebusinessCoronary artery abnormalitiesmedicine.drug
researchProduct

Anakinra drug retention rate and predictive factors of drug survival in systemic juvenile idiopathic arthritis and adult onset Still’s disease.

2019

Introduction: Only a few studies have reported the long-term efficacy of interleukin (IL)-1 inhibition in systemic juvenile idiopathic arthritis (sJIA) and adult onset Still’s disease (AOSD). We herein describe Anakinra (ANA) effectiveness expressed in terms of drug retention rate (DRR) and evaluate predictive factors of drug survival in sJIA and ASOD patients. Objectives: Examine the overall DRR of ANA in sJIA and AOSD patients. Explore the influence of biologic line of treatment, and the concomitant use of disease modifying anti-rheumatic drugs (cDMARDs) on DRR in the whole sample and stratified according to the disease thereafter; find eventual predictive factors associated with events l…

Settore MED/38 - Pediatria Generale E SpecialisticaAnakinraSettore MED/16 - REUMATOLOGIAAnakinra Systemic Juvenile Idiopathic Arthritis Still’s disease
researchProduct

Pediatric Recurrent Pericarditis: Appropriateness of the Standard of Care and Response to IL-1 Blockade

2022

Objective: To analyze, in a cohort of pediatric patients with recurrent pericarditis undergoing anti-interleukin (IL)-1 treatment: the agent and dosing used as first-line treatment, the long-term efficacy of IL-1 blockers, the percentage of patients achieving a drug-free remission, and the presence of variables associated with drug-free remission. Study design: Data were collected from patients' charts. The annualized relapse rate (ARR) was used for evaluation of treatment efficacy, and bivariate logistic regression analysis was used for variables associated with drug-free remission. Results: Fifty-eight patients, treated between 2008 and 2018, were included in the study (mean follow-up. 2.…

anti-inflammatory agents nonsteroidal colchicine interleukin-1 pericarditis steroids therapytherapySettore MED/38 - Pediatria Generale E SpecialisticaSettore MED/09 - Medicina Internaanti-inflammatory agents non-steroidal; colchicine; interleukin-1; pericarditis; steroids; therapyanti-inflammatory agents nonsteroidalanti-inflammatory agents non-steroidalPediatrics Perinatology and Child Healthanti-inflammatory agents nonsteroidal; colchicine; interleukin-1; pericarditis; steroids; therapypericarditiscolchicineinterleukin-1steroidsThe Journal of Pediatrics
researchProduct

The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy.

2015

Autoinflammatory disorders (AIDs) are a novel class of diseases elicited by mutations in genes regulating the homeostasis of innate immune complexes, named inflammasomes, which lead to uncontrolled oversecretion of the proinflammatory cytokine interleukin-1β. Protean inflammatory symptoms are variably associated with periodic fever, depicting multiple specific conditions. Childhood is usually the lifetime in which most hereditary AIDs start, though still a relevant number of patients may experience a delayed disease onset and receive a definite diagnosis during adulthood. As a major referral laboratory for patients with recurrent fevers, we have tested samples from 787 patients in the perio…

Adultmedicine.medical_specialtyReferralProinflammatory cytokineDiagnosis DifferentialRheumatologyAcquired immunodeficiency syndrome (AIDS)Internal medicinePeriodic feverMedicineHumansAge FactorChildGenetic disorderInnate immune systembusiness.industryHereditary Autoinflammatory DiseasesAge FactorsGeneral Medicinemedicine.diseaseAdulthoodInterleukin-1βRheumatologyImmunity InnateHereditary Autoinflammatory DiseasePeriodic feverSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyRecurrent feverImmunologyAutoinflammationbusinessAutoinflammatory DisordersHuman
researchProduct

Additional file 3 of Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during S…

2021

Additional file 3: Appendix 3. Laboratory comparison between Kawasaki Disease patients seen during SARS-CoV-2 epidemic and a Historical Cohort of Kawasaki Disease Patients.

hemic and lymphatic diseasescardiovascular diseasesskin and connective tissue diseases
researchProduct

Typical Kawasaki disease with atypical pneumonia: a paediatric case report.

2020

Patients with complete Kawasaki disease (KD), in approximately 10–20% of cases, fail to defervesce with intravenous immunoglobulin (IVIG) infusion and acetylsalicylic acid (ASA) (1–5). Failure is u...

Malemedicine.medical_specialtyImmunologyMEDLINEMucocutaneous Lymph Node SyndromeMethylprednisolone03 medical and health sciences0302 clinical medicineRheumatologyhemic and lymphatic diseasesImmunology and AllergyMedicineHumans030212 general & internal medicineGlucocorticoids030203 arthritis & rheumatologybiologybusiness.industryImmunoglobulins IntravenousGeneral MedicinePneumoniamedicine.diseaseDermatologyKawasaki diseaseatypical pneumoniaIVIG treatmentpaediatric caseTreatment OutcomeAtypical pneumoniaChild Preschoolbiology.proteinKawasaki diseaseAntibodybusinessTomography X-Ray ComputedScandinavian journal of rheumatology
researchProduct